Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Abdomen and Pelvis CT to rule out Pancreatic Cancer | n/a | Decision document | South and West Hertfordshire | |
| Anastrozole | Familial breast cancer | n/a | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bladder-Renal Cancer | Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Brain and Central Nervous System Cancers | n/a | Clinical pathways | East and North Hertfordshire | |
| Brain MRI for the exclusion of Brain and CNS Cancer | n/a | n/a | South and West Hertfordshire | |
| Breast Cancer - Suspected (Adults >16 years) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Breast Screening Service | n/a | Patient information | Hertfordshire and West Essex ICB | |
| Children's Cancer | n/a | Patient information | Hertfordshire and West Essex ICB | |
| Chlorambucil | Cancer indications | Red | n/a | Hertfordshire and West Essex ICB |
| Chlormethine gel | Mycosis fungoides-type cutaneous T-cell lymphoma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Community Breast Pain | n/a | Clinical pathways | East and North Hertfordshire | |
| CT Request and 2WW Non-Specific Symptoms Referral Pathway | n/a | Clinical pathways | South and West Hertfordshire | |
| Dasatinib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Denosumab Xgeva® | Prevention of skeletal-related events (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Erlotinib | All indications (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
| Etoposide | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Exemestane | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Faecal Immunochemical Test (FIT) process pathway for suspected Lower GI Cancer | n/a | Clinical pathways | Hertfordshire and West Essex ICB, South and West Hertfordshire | |
| Fulvestrant | Locally advanced or metastatic breast cancer | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Goserelin | Prostate cancer - 2nd line | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Gynaecological Cancers - Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Haematological Cancer – Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Head and Neck Cancer - Suspected | n/a | Clinical pathways | East and North Hertfordshire | |
| Ibandronic acid 50mg | Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Ibrutinib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Imatinib | All indications (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Lenalidomide | Multiple myeloma follicular lymphoma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Letrozole | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Leuprorelin | Prostate cancer - 2nd line | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Lower GI/Colorectal Cancer Suspected | n/a | Clinical pathways | East and North Hertfordshire, South and West Hertfordshire | |
| Lung Cancer - Suspected | n/a | Clinical pathways | East and North Hertfordshire, South and West Hertfordshire | |
| Lymphoedema Services – Specialist treatment in the private sector | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Male LUTS | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Melphalan | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Mesna | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Methotrexate 10mg | Autoimmune disease | Double Red | n/a | Hertfordshire and West Essex ICB |
| Methotrexate 2.5mg | Autoimmune disease | Amber protocol | Prescribing guideline | Hertfordshire and West Essex ICB |
| Methoxsalen | Cancer, psoriasis | Red | n/a | Hertfordshire and West Essex ICB |
| Mitomycin | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Mitotane | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Nintedanib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Palbociclib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Peginterferon and ropeginterferon | Myeloproliferative neoplasms (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Pegvisomant | Acromegaly (NHSE tertiary centre only) | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Prostate Cancer - Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| PSA Pathway | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Raloxifene | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Reducing medicines waste in care homes - Care home staff | Care homes | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Relugolix (Orgovyx) | Hormone-sensitive prostate cancer | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ruxolitinib | Myelofibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Sarcoma - Suspected Cancer | n/a | Clinical pathways | East and North Hertfordshire | |
| Sirolimus oral | Transplant rejection (prescribe by brand) NHSE for existing patients | Amber protocol | n/a | Hertfordshire and West Essex ICB |
| Skin Cancer Suspected - Pigmented Lesion/ Melanoma/ SCC/ BCC | n/a | Patient information | Hertfordshire and West Essex ICB | |
| Sodium clodronate | Bone pain, hypercalcaemia of malignancy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Tacrolimus oral | Transplant rejection (prescribe by brand) NHSE for existing patients | Amber protocol | n/a | Hertfordshire and West Essex ICB |
| Tamoxifen | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Thalidomide | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Tioguanine | Leukaemia | Red | n/a | Hertfordshire and West Essex ICB |
| Tretinoin | Cancer (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
| Triptorelin as Decapeptyl SR®– Gonadorelin analogue of choice within licensed indications | Prostate cancer - 1st line | Green | n/a | Hertfordshire and West Essex ICB |
| Urology Cancer - Suspected (excluding Prostate) | n/a | Clinical pathways | Hertfordshire and West Essex ICB |